文献速递淋巴瘤血栓与止血

慢性淋巴细胞白血病患者中COVID-19及新冠后状态的演变格局:欧洲慢性淋巴细胞白血病研究计划(ERIC)的一项研究

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
PubMed 文献 · Am J Hematol · 2023-09-29

这项回顾性国际多中心研究分析了2020年1月至2022年5月期间1540例感染SARS-CoV-2的慢性淋巴细胞白血病及相关疾病患者的临床特征与结局,按疫情阶段分为四期。晚期阶段患者合并症负担更重但住院、ICU入住和死亡更少,4个月总生存率从68%升至83%(P=0.0015)。6.65%的幸存者发生再感染,16.5%发展为新冠后状态,感染严重程度是唯一危险因素,中位缓解时间4.7个月。

要点

  • 疫情晚期阶段患者合并症负担更重,但住院、ICU入住和死亡均较早期阶段减少。
  • 4个月总生存率随疫情阶段改善,从68%升至83%(P=0.0015)。
  • 年龄、合并症、CLL定向治疗是死亡危险因素,疫苗接种状态不是。

核心结论

  • 慢性淋巴细胞白血病患者的总生存率在疫情不同阶段有所改善,可能归因于针对SARS-CoV-2的预防和治疗措施的改进以及更温和变异株的出现。
  • 然而死亡率仍然相关,相当数量患者发展为新冠后状态,需要进一步研究。

研究设计与样本

  • 回顾性国际多中心研究,纳入2020年1月至2022年5月期间1540例感染SARS-CoV-2的慢性淋巴细胞白血病及相关疾病(小淋巴细胞淋巴瘤和高计数单克隆B淋巴细胞增多症)患者。
  • 按病例处置和SARS-CoV-2变异株出现将患者分配至四个阶段。
  • 新冠后状态根据WHO标准定义。

主要发现

  • 疫情最近阶段感染的患者虽然合并症负担更高,但与初始阶段感染患者相比,住院更少、很少需要重症监护室入住或死亡。
  • 4个月总生存率随阶段改善,从68%升至83%,P=0.0015。
  • 年龄、合并症、CLL定向治疗是死亡危险因素,而疫苗接种状态不是。
  • 幸存者中6.65%发生再感染,通常较初始感染更轻;16.5%发展为新冠后状态。
  • 新冠后状态以疲劳、呼吸困难、持续咳嗽和注意力受损为特征;感染严重程度是发生新冠后状态的唯一危险因素;新冠后状态的中位缓解时间为4.7个月。

关键数值与推荐

  • 新冠后状态根据WHO标准定义。
  • 4个月总生存率从68%升至83%,P=0.0015。
  • 幸存者中再感染率6.65%,新冠后状态发生率16.5%,新冠后状态中位缓解时间4.7个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Visentin A, Chatzikonstantinou T, Scarfò L, et al. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. Am J Hematol. 2023. PMID: 37772428. doi:10.1002/ajh.27093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。